baber/WOPTO huggingface dataset:
Patent NZ-270524-A (NZ)
Title: Curable ink containing an epoxide; overlaying ink design with decorative foil
Inventor: KAMEN MELVIN EDWIN
IPC: C09D11/10
Filed: 1995-02-20
Abstract: d) Radiation-curable polymer composition, for use in a method for decorating substrates with hot-stamping foil, which composition comprises 10 90% (preferably 35 - 90%) of a radiation-curable cycloaliphatic epoxide, 1 - 20% (preferably 3 - 15%) of an ester-containing polyol, preferably with a molecular weight less than 850 and viscosity less than 60 Pa.s, e.g. a polycaprolactone polyol, and 1 - 20% (preferably 3 - 15%) of a defoaming agent e.g. polyvinylbutylether. The composition preferably contains an adhesion-promoter, e.g. 1 - 10% of a silane; and/or when the composition is to be cured by actinic radiation it also desirably comprises a photoinitiator, e.g. 0.5 - 20% (preferably 3 to 15%) of a carbonyl compound and/or a photosensitive onium salt. It may comprise 1 - 50% of pigment.
Patent NZ-304437-A (NZ)
Title: Octa- or nona-peptides and therapeutic agent for autoimmune diseases containing the same
Inventor: YAMAGATA NOBUYUKI
IPC: C07K14/705
Filed: 1996-04-03
Abstract: The present invention relates to a peptide having the following amino acid sequence:     Ala-Xaa1-Leu-Xaa2-Phe-Xaa3-Xaa4-Xaa5-(Xaa6)n (wherein Xaa1 and Xaa4 each independently represents an amino acid residue which may have an alkyl or heteroalkyl side chain which may be substituted by a hydroxy, amino or guanidyl group; Xaa2 and Xaa6 each independently represents an amino acid residue which may have an alkyl or heteroalkyl side chain which may be substituted by a hydroxyl group; Xaa3 and Xaa5 each independently represents an amino acid residue which may have a hydrophobic side chain; and   n stands for 1 or 0),  or derivatives thereof; and a modification thereof. The peptide or derivatives thereof according to the present invention is useful as a pharmaceutical composition for the prevention and treatment of autoimmune diseases, rejection reaction attendant on the organ transplantation, inflammation or the like.
Patent NZ-329990-A (NZ)
Title: Partition including vertical sliding panels, support for end panel slidable with respect to panel
Inventor: BISCHOF MARKUS
IPC: E05D15/00
Filed: 1997-05-02
Abstract: A sliding partition is made up of several vertical panels 2, 4 sliding in a guide rail in the ceiling.  The guide rail has a 90° curve 21 at one end.  The panel 2 that forms the end of the partition that abuts against a wall 3 has two sliding supports 5, 6, the support 6 trailing the support 5 when the panels are moved to the closed position.  The support 6 is able to move relative to the panel 4, the movement being driven by a drive unit within the support 6.  This allows the end partition 4 to be moved as shown into a position where it is flush with the other panels 2, and abuts a stop 16.  This eliminates any gap between the end panel and the wall 3 which would otherwise need an extra flap or shutter to close it.
Patent NZ-331446-A (NZ)
Title: use of uridine triphosphates and related compounds to treat otitis media
Inventor: DRUTZ DAVID J
IPC: A61K31/70
Filed: 1997-02-14
Abstract: A triphosphate compound of formula I, II, III or IV or a pharmaceutically acceptable salt thereof is used in the manufacture of a medicament for treating otitis media in a patient. The medicament is administered to the middle ear of the patient to promote fluid drainage from the middle ear. In formula I: X1, X2 and X3 are independently OH or SH; R1 is -O-, imido, methylene or dihalomethylene and R2 is H or Br. In formula II: R1 and X1-X3 are as defined above; R3 and R4 are H when R2 is not present and there is a double bond between N-1 and C-6 (adenine); R3 and R4 are H while R2 is -O- and there is a double bond between N-1 and C-6 (adenine-1-oxide) or R2, R3 and R4 together are -CH=CH-, forming a ring from N-6 to N-1 with a double bond between N-6 and C-6 (1,N6-ethenoadenine). In formula III: R1 and X1-X3 are as defined above; R5 and R6 are H when R7 is not present and there is a double bond between N-3 and C-4 (cytosine) or R5, R6 and R7 together are -CH=CH-, forming a ring from N-3 to N-4 with a double bond between N-4 and C-4 (3,N4-ethenocytosine). In formula IV: B is adenine or uracil.
Patent NZ-334442-A (NZ)
Title: 3,6-ketal and enol ether macrolide antibiotics
Inventor: BERTINATO PETER
IPC: A61P31/04
Filed: 1999-03-02
Abstract: 3,6-ketal and enol ether macrolide antibiotics of the formula 1 or 2 where X is -CH(-NR9R10)-, -CH(Or3)-, -C(O)-, -CH2NR6-, -NR6CH2-, or -C(=NR5)- , wherein the first dash of each of the foregoing X groups is attached to the C-10 carbon of the compounds of formulas 1 and 2 and the last dash is attached to the C-8 of the compounds of formula 1 and 2 X1 is formula 3 R1 and R2 are OH Or R2 is O and r1 is X2 and they are taken together as follows -formula 4 X2 is O, -N(NR7R8)-, or -N(R7)- The other substituents are defined in the specification. These antibiotics are used to treat bacterial, parasitic and protozoal infections.
Patent NZ-335365-A (NZ)
Title: Polymer light emitting diode containing at least one semi-conducting polymer adapted for electron transport and/or hole blocking
Inventor: SAMUEL IFOR DAVID WILLIAM
IPC: H01L51/50
Filed: 1997-11-07
Abstract: The device such as a light emitting diode comprises a plurality of component layers with: a)	a first outer layer being used for electron injection; b)	a second opposing outer layer being used for "hole" injection and c)	a plurality of intermediate layers arranged therebetween being used for charge semi-conduction comprising at least one semi-conducting polymer.  The semi-conducting polymer comprises a polymer selected from a nitrogen and/or sulphur containing polymer that is partially or substantially conjugated.  The ratio of thicknesses of the semi-conducting polymer layers is 0.1-10 with the least thick layer being the least efficient semi-conductor.
Patent NZ-336839-A (NZ)
Title: Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
Inventor: HSEI VANESSA
IPC: A61K47/48
Filed: 1998-02-20
Abstract: A polypeptide selected from the group consisting of: 1) a polypeptide that is an anti-IL-8 monoclonal antibody or antibody fragment comprising a light chain amino acid sequence comprising the complementary determining regions of the light chain polypeptide amino acid sequence of Fig 36 and 2) a polypeptide that is an anti-IL-8 monoclonal antibody or antibody fragment comprising a light chain amino acid sequence comprising the complementary determining regions of the light chain polypeptide amino acid sequence of Fig 45 Also disclosed is the method of producing such polypeptides and their use in the treatment of inflammatory disorders including adult respiratory distress syndrome, hypovolemic shock, ulcerative colitis and rheumatoid arthritis.
Patent NZ-507489-A (NZ)
Title: Fluid energy milling process and apparatus
Inventor: HATTON ANTHONY GUY
IPC: B02C19/06
Filed: 1999-04-19
Abstract: Micronised calcium mupirocin dihydrate having a moisture content of from 3.0 to 4.0% and an amorphous content of 5% or less, and a fluid energy milling apparatus including means for adjusting humidity of the compressed air used for milling micronised calcium mupirocin dihydrate, which is useful as a drug substance in pharmaceutical compositions.
Patent NZ-509122-A (NZ)
Title: Wound healant comprising activated growth from platelets and ascorbic acid
Inventor: WORDEN CHARLES E
IPC: A61K35/19
Filed: 1999-06-21
Abstract: A  method  of  making  a  wound  healant  composition comprising    activating   a   composition   comprising    a therapeutically  effective amount  of  platelet  concentrate and  an  effective  gel  viscosity  preservation  amount  of ascorbic acid.
Patent NZ-511868-A (NZ)
Title: Device for preparing hot beverages and method for preparing hot beverages using said device
Inventor: JORGENSEN CARSTEN
IPC: A47J31/30
Filed: 1999-11-25
Abstract: A device for preparing beverages of the type having a closed compartment (c2), an open compartment (c1), an ascension pipe (23) connecting the compartments, and a filtering device (f1) between the ascension pipe (23) and the open compartment (c1), has some disadvantages in that an external heating source is needed, thereby increasing the risk of fire and burning the operating persons. Further, the infusion time is either fixed, being decided by the distance between the lower orifice of the ascending pipe and the bottom of the closed compartment or left to the user to estimate. The inventor has consequently suggested, that the bottom of the closed compartment (c2) at least has two levels (H1, H4), one level of diminished elevation (H4) in a relatively small area around the lower orifice of the ascension pipe (23), the level (H3) of which is at least below the other elevated level (H1) of a relatively large area, said large area being equipped with electrical heating means (he1, he2) controlled by switching means and at least one temperature sensitive means (not shown) for controlling the switching means, said large area of the bottom being surrounded by a rim (not shown) for holding a residue of liquid.
Patent NZ-515076-A (NZ)
Title: Refrigerator storage tray
Inventor: CHADWICK LESTER
IPC: B65D1/36
Filed: 2000-06-15
Abstract: A  storage  tray for use in a refrigerator,  the  tray including  a body which has a plurality of openings  in  the body,  and  formations  on  the  body  which  are  slidingly engageable with guides.
Patent NZ-518372-A (NZ)
Title: Polycyclic quinone and ionophore composition for the synergistic reduction of methane formation in ruminant animals
Inventor: BALLINGER KENNETH E
IPC: A23K1/18
Filed: 2000-10-10
Abstract: A composition comprising at least one polycyclic quinone and at least one ionophore compound in synergistic amounts effective to reduce methane formation in ruminants when administered. Examples of polycyclic quinone include anthraquinone and anthrahydroquinone compounds. The method of administering is the said composition is disclosed.
Patent NZ-518791-A (NZ)
Title: Treatment of osteoporsis, Paget's disease and other bone mineral density disesases using calcitonin and DHEA (an androgen)
Inventor: SCHWARTZ KENNETH E
IPC: A61P37/06
Filed: 2000-11-13
Abstract: A pharmaceutical formulation and it's use comprising a calcitonin-like agent and a dehydroepiandrosterone (DHEA)- like agent for the preparation of a pharmaceutical composition for increasing an individual's bone mineral density (BMD) wherein said medicament is formulated to provide the calcitonin-like and DHEA-like agents in an amount effective to increase BMD, and wherein administration of said medicament potentiates any increase in BMD achieved by administration of a similar amount of a calcitonin-like agent alone.
Patent NZ-523196-A (NZ)
Title: Apparatus and method for grinding webs made of fiber material
Inventor: AHONEN HEIKKI
IPC: D21H25/00
Filed: 1999-07-22
Abstract: Apparatus for grinding of paper, cardboard or a similar continuous web (16) manufactured from vegetative based fibrous raw-material, the apparatus comprising a frame (1), means (4, 8) fitted to the frame for guiding the web along a predetermined path, at least two treatment means means (2, 6, 10) which include a grinding surface which can be brought into contact with the moving web, and means for transferring at least one grinding surface at least partially transversally against the direction of the moving web for adjusting a grinding force between the web and the grinding surface, and the contact length between the grinding surface and the web and a web tension. The treatment means further includes either successively arranged grinding rolls or rollers or belt grinding stations arranged on one side of the web and regulating rolls arranged on the opposite side of the web or a plurality of grinding surfaces which are deflected from the direction of motion of the web and which can be brought into contact with the web, the relative position of the web and the grinding surface being adjustable for regulation of the web tension and, thus, of the intensity of the grinding.
Patent NZ-523251-A (NZ)
Title: Distortion-free image contrast enhancement
Inventor: JAMES BRIAN G
IPC: G06K9/00
Filed: 2001-07-05
Abstract: An image, such as an X-ray, is enhanced through local enhancement of the contrast of the image's point intensities. A first, low frequency upper curve is fitted to the local maximums and a second independent, low frequency lower curve is fit to the local minimums, forming a fairway with the raw image data residing therebetween. A local range, between the fairway local maximum intensity and fairway local minimum intensity, is extracted for each point. Each point is scaled by the ratio between the fairway's local range and the dynamic range for the image so as to maximize its variation in intensity between it and its neighboring points. Preferably an iterative moving average technique is used to establish the fairway curves. In a preferred embodiment, outlier points scaled outside the fairway are temporarily stored at higher precision than the dynamic range. A histogram of the fairway corrected data is formed, having a range greater than the dynamic range and encompassing substantially all the outlier points. Only the most deviant of the outliers are trimmed in this histogram correction and the resulting range limits for the entire image are scaled to the dynamic range.
Patent NZ-524356-A (NZ)
Title: Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells
Inventor: SCHULER GEROLD
IPC: C12Q1/02
Filed: 2001-08-24
Abstract: A method for the preparation of ready-for-use cryoconserved mature dendritic cells, comprising (a) providing immature dendritic cells (DC); (b) culturing the immature DCs in a culture medium containing a maturing cocktail with one or more maturing stimulants to obtain mature DCs; (c) freezing the mature DCs in a freezing medium which does not contain any heterologous serum.
Patent NZ-524612-A (NZ)
Title: OB fusion protein compositions and methods
Inventor: MANN MICHAEL BENJAMIN
IPC: A61K48/00
Filed: 1997-12-11
Abstract: Disclosed is a DNA sequence and uses thereof , where said DNA sequence encodes a fusion protein optionally having an N-terminal methionine , comprising an antibody constant region or portion thereof attached to the N-terminus of a human OB protein . Such nucleotide sequences and proteins encoded by them are useful in treatment of excess weight , diabetes , high blood lipid level , arterial sclerosis , arterial plaques , insufficient lean muscle mass , insufficient sensitivity to insulin , gall stone formation , and stroke .
Patent NZ-525820-A (NZ)
Title: Mutant allergens
Inventor: HOLM JENS
IPC: A61K38/095
Filed: 2001-11-16
Abstract: A recombinant allergen such as an inhalation allergen, specifically Bet v1, that is a mutant of a naturally occurring allergen, wherein the mutant allergen has at least four mutation, which each reduce the specific IgE binding capability of the mutant allergen as compared to the IgE binding capability of the naturally occurring allergen, wherein each mutation is a substitution of one surface-exposed amino acid residue with another residue, which does not occur in the same position in the amino acid sequence of any known homologous protein within the taxonomic species from which the naturally occurring allergen originates, characterized in that at least four mutations (primary mutations) are mutually spaced by at least 15 angstrom and wherein the primary mutations are placed in such a manner that at least one circular surface region with a area of 800 angstrom2 comprises no mutation.
Patent NZ-526543-A (NZ)
Title: Thiazole derivatives for treating PPAR related disorders
Inventor: CADILLA RODOLFA
IPC: A61P25/00
Filed: 2001-12-19
Abstract: Compounds of formula (I) that are used for the treatment of hPPAR mediated diseases or conditions are disclosed, wherein the variables are as defined in the specification.
Patent NZ-527691-A (NZ)
Title: Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
Inventor: SLASSI ABDELMALIK
IPC: A61K31/4439
Filed: 2002-02-19
Abstract: Disclosed herein are oxadiazole compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors (mGluR), and that are useful for treating neurological diseases and disorders. Method of preparing the compounds is also disclosed.
Patent NZ-527861-A (NZ)
Title: Suppression of allergic reactions by immunization against IgE using a vaccine comprising lactic acid bacteria which have recombinant surface polypeptides
Inventor: STADLER BEDA MARTIN
IPC: A23K1/00
Filed: 2002-03-04
Abstract: Strains of lactic acid bacteria capable of reducing an individual's tendency to react in an allergic manner to a variety of different allergens are described. Particularly described are recombinant strains of lactic acid bacteria that express surface polypeptides which include peptides or antibody fragments acting as mimic for at least a part of the Fc region of IgE-molecules. Also described are foodstuffs and/or pharmaceutical compositions containing the micro-organisms or active fractions thereof.
Patent NZ-532802-A (NZ)
Title: Nicotin-or isonicotin benzothiazole derivatives
Inventor: FLOHR ALEXANDER
IPC: A61P37/08
Filed: 2002-11-11
Abstract: Described are compounds of the general formula (IA) or (IB) wherein R1 is phenyl, piperidin-1-yl or morpholinyl; A is -O- and R is-(CH2)n-N(R'')-C(O)-lower alkyl, -(CH2)n-O-lower alkyl, -(CH2)n-O-(CH2)n-O-lower alkyl, lower alkyl, -(CH2)n- morpholinyl, -(CH2)n-phenyl,-(CH2)n-N(R'')2, (CH2)n-pyridinyl, -(CH2)n-CF3, (CH2)n-2-oxo-pyrrolidinyl or C4-6- cycloalkyl; '' is independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is-N(R')- and R is lower alkyl, C4-6-cycloalkyl, -(CH2)n-O-lower alkyl, -(CH2)n-pyridinyl, -(CH2)n-piperidinyl, -(CH2)n-phenyl, (CH2)n- N(R'')-C(O)-lower alkyl, -(CH2)n-morpholinyl, or (CH2)n-N('')2; R' and R'' are independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is CH2- and R is-N(R'')-(CH2)m-O-lower alkyl, -N(R'')2 S-lower alkyl, or is acetidinyl, pyrrolidinyl or piperidinyl, which is optionally substituted by hydroxy or lower alkoxy or is morpholinyl, -N(R'')-CH2)m-C4-6-cycloalkyl, -N(R'')-(CH2)m-C(O)O-lower alkyl, -N(R'')-(CH2)m-C(O)OH, -2-oxo pyrrolidinyl, -N(R'')-C(O)O-lower alkyl, -O(CH2)m-O-lower alkyl; R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3; or A is S- and R is lower alkyl; or A-R are together piperazinyl, substituted by lower alkyl, -C(O)-lower alkyl or a oxo group, or is piperidinyl, substituted by lower alkoxy or hydroxy, or is morpholinyl, substituted by lower alkyl, or is C4-6-cycloalkyl, -azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, thiomorpholine-1,1-dioxo, -tetrahydopyran or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl; Also described is the use of compounds of general formula I, which are adenosine receptor ligands. Specifically, the compounds a good affinity to the A2A-receptor and a high selectivity to the A1 and A3 receptors.
Patent NZ-533466-A (NZ)
Title: Microfabricated elastomeric valve and pump systems
Inventor: UNGER MARC A
IPC: F04B43/04
Filed: 2000-06-27
Abstract: A method of fabricating an elastomeric structure, comprising : forming a first elastomeric layer on top of a first micromachined mold, the first micromachined mold having a first raised protrusion which forms a first recess extending along a bottom surface of the first elastomeric layer; forming a second elastomeric layer on top of a second micromachined mold, the second micromachined mold having a second raised protrusion which forms a second recess extending along a bottom surface of the second elastomeric layer; bonding the bottom surface of the second elastomeric layer onto a top surface of the first elastomeric layer such that a control channel forms in the second recess between the first and second elastomeric layers; and positioning the first elastomeric layer on top of a planar substrate such that a flow channel forms in the first recess between the first elastomeric layer and the planar substrate. Various embodiments are disclosed. (62) Divided out of 516519
Patent NZ-534599-A (NZ)
Title: Cross-linkable and/or cross-linked nanofiller compositions
Inventor: MAYER HANS ANTON
IPC: C08K9/00
Filed: 2003-03-28
Abstract: Disclosed is a cross-linkable and/or cross-linked nanofiller composition which comprises a cross-linkable and/or cross-linked ethylene (co)polymer and intercalated nanofiller. Also disclosed are processes for preparing the nanofiller composition, articles composed of the nanofiller composition and processes for preparing the articles.
Patent NZ-535694-A (NZ)
Title: A dressing mechanism with elastic end sections with openings and laminated central section
Inventor: BEAUDRY WALLACE J
IPC: A61F5/56
Filed: 1997-01-17
Abstract: Ends of latex strip 321 are adhered between layers 315 and 319 to form anchors 301 and 303. Stiffening material 323 is adhered across the mid-section of the latex strip 321 and a pad 314 is adhered to the underside of the strip. Each of the anchors 301 and 303 has adhesive 327 applied to its underside, and has at least one opening 383. (62) Divided Out of 521283
Patent NZ-537221-A (NZ)
Title: Detection of a secreted polypeptide on the surface of a cell used as a marker for cellular productivity of the secreted polypeptide
Inventor: THILL GREG
IPC: C12Q1/68
Filed: 2003-05-20
Abstract: Methods of detecting a secreted polypeptide produced by a cell, and methods for selecting a cell that produces high levels of the secreted polypeptide are described. Such methods can be used to select a cell producing high levels of a secreted polypeptide encoded by a heterologous nucleic acid that has been introduced into the cell.
Patent NZ-564407-A (NZ)
Title: Tablet containing hardly soluble active ingredient ((S)-N-[2-(1,6,7,S-tetrahydro-2H-indeno[5,4-b]furan-S-yl)ethyl]propionamide)
Inventor: MARUNAKA SHIGEYUKI
IPC: A61K9/28
Filed: 2006-06-21
Abstract: Disclosed is a tablet containing about 3-50% by weight of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide based on the whole tablet, magnesium stearate, and hydroxypropylcellulose having a viscosity of about 1-4 mPa s.
Patent NZ-570462-A (NZ)
Title: Plasma Coated Electrical Devices
Inventor: COULSON STEPHEN
IPC: B05D7/00
Filed: 2007-01-19
Abstract: An electrical or electronic device having a polymeric coating, formed by exposing said device to pulsed plasma comprising a compound of formula (I), wherein the variables are as defined in the specification, for a sufficient period of time to allow a polymeric layer to form on the surface of the electrical or electronic device. Particularly preferred compound of formula (I) is 1H, 1H, 2H, 2H-heptadecafluorodecyl acrylate. The electrical or electronic device may be selected from communications devices, sound or audio systems devices, computers or computer-related components, outdoor lighting systems, or electrical or electronic devices used in transport vehicles, washing machines and dishwashers or components of any of these devices.
Patent NZ-571868-A (NZ)
Title: Novel alpha-galactoside-beta-2,6-sialyltransferase, gene coding for the transferase and process for producing the same
Inventor: TSUKAMOTO HIROSHI
IPC: C12N1/20
Filed: 2006-08-10
Abstract: Provided is an isolated protein having beta-galactoside-alpha-2,6- sialyltransferase activity comprising a specified amino acid sequence or sharing an amino acid identity of 70% or more with it. Further provided are corresponding nucleic acid sequences, vectors and host cells containing the sequences and a deposited bacterial strain expressing the protein.